HMGB1 enhances the protumoral activities of M2 macrophages by a RAGE-dependent mechanism

作者: Armando Rojas , Fernando Delgado-López , Ramón Perez-Castro , Ileana Gonzalez , Jacqueline Romero

DOI: 10.1007/S13277-015-3940-Y

关键词: RAGE (receptor)Cancer researchTumor necrosis factor alphaTumor microenvironmentHMGB1Interleukin 10MacrophageInflammationMacrophage polarizationBiology

摘要: The monocyte-macrophage lineage shows a high degree of diversity and plasticity. Once they infiltrate tissues, may acquire two main functional phenotypes, being known as the classically activated type 1 macrophages (M1) alternative 2 (M2). M1 phenotype can be induced by bacterial products interferon-γ exerts cytotoxic effect on cancer cells. Conversely, alternatively M2 is Il-4/IL13 promotes tumor cell growth vascularization. Although receptor for advanced glycation end-products (RAGE) engagement in has been reported several groups to promote inflammation, nothing about functionality RAGE macrophages. In current study, we demonstrate that equally expressed both macrophage phenotypes activation high-mobility group protein box1 (HMGB1) protumoral activities MKN45 cells co-cultured with treated HMGB1 at different times displayed higher invasive abilities. Additionally, conditioned medium from HMGB1-treated angiogenesis vitro. RAGE-targeting knockdown abrogates these activities. Overall, present findings suggest contribute, RAGE-dependent mechanism, phenotype.

参考文章(42)
Fernando O. Martinez, Siamon Gordon, Massimo Locati, Alberto Mantovani, Transcriptional Profiling of the Human Monocyte-to-Macrophage Differentiation and Polarization: New Molecules and Patterns of Gene Expression Journal of Immunology. ,vol. 177, pp. 7303- 7311 ,(2006) , 10.4049/JIMMUNOL.177.10.7303
Yunlu Xu, Fatouma Toure, Wu Qu, Lili Lin, Fei Song, Xiaoping Shen, Rosa Rosario, Joel Garcia, Ann Marie Schmidt, Shi-Fang Yan, Advanced Glycation End Product (AGE)-Receptor for AGE (RAGE) Signaling and Up-regulation of Egr-1 in Hypoxic Macrophages Journal of Biological Chemistry. ,vol. 285, pp. 23233- 23240 ,(2010) , 10.1074/JBC.M110.117457
Daolin Tang, Rui Kang, Herbert J. Zeh III, Michael T. Lotze, High-mobility group box 1 and cancer Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms. ,vol. 1799, pp. 131- 140 ,(2010) , 10.1016/J.BBAGRM.2009.11.014
U. G. Andersson, K. J. Tracey, HMGB1, a pro-inflammatory cytokine of clinical interest: introduction. Journal of Internal Medicine. ,vol. 255, pp. 318- 319 ,(2004) , 10.1111/J.1365-2796.2003.01304.X
Prabhakaran Kumar, Somasundaram Raghavan, Gobinath Shanmugam, Narkunaraja Shanmugam, Ligation of RAGE with ligand S100B attenuates ABCA1 expression in monocytes. Metabolism-clinical and Experimental. ,vol. 62, pp. 1149- 1158 ,(2013) , 10.1016/J.METABOL.2013.02.006
Alberto Mantovani, Tiziana Schioppa, Chiara Porta, Paola Allavena, Antonio Sica, Role of tumor-associated macrophages in tumor progression and invasion. Cancer and Metastasis Reviews. ,vol. 25, pp. 315- 322 ,(2006) , 10.1007/S10555-006-9001-7
Alberto Mantovani, Antonio Sica, Paola Allavena, Cecilia Garlanda, Massimo Locati, Tumor-associated macrophages and the related myeloid-derived suppressor cells as a paradigm of the diversity of macrophage activation. Human Immunology. ,vol. 70, pp. 325- 330 ,(2009) , 10.1016/J.HUMIMM.2009.02.008
José Augusto Nogueira-Machado, Caroline Maria de Oliveira Volpe, Clara Araujo Veloso, Miriam Martins Chaves, HMGB1, TLR and RAGE: a functional tripod that leads to diabetic inflammation Expert Opinion on Therapeutic Targets. ,vol. 15, pp. 1023- 1035 ,(2011) , 10.1517/14728222.2011.575360
Subhra K. Biswas, Paola Allavena, Alberto Mantovani, Tumor-associated macrophages: functional diversity, clinical significance, and open questions Seminars in Immunopathology. ,vol. 35, pp. 585- 600 ,(2013) , 10.1007/S00281-013-0367-7
Joyce A Schroeder, Melissa C Adriance, Melissa C Thompson, Todd D Camenisch, Sandra J Gendler, MUC1 alters β -catenin-dependent tumor formation and promotes cellular invasion Oncogene. ,vol. 22, pp. 1324- 1332 ,(2003) , 10.1038/SJ.ONC.1206291